The GALILEO trial has been halted after an early peek at the data showed that rivaroxaban (Xarelto; Bayer/Janssen) was associated with greater risks of all-cause mortality, thromboembolic events, and ...

New questions are being raised about the clinical trial of a widely used heart drug, and critics are calling for an independent investigation, after a medical device used during the study was later ...

BOSTON, MA—For patients undergoing transradial coronary procedures, a short course of rivaroxaban (Xarelto; Bayer/Janssen) reduces the rate of radial artery occlusion without significantly increasing ...

Perugia, Italy - Promising phase 2 results with the new oral direct factor Xa inhibitor anticoagulant rivaroxaban (Bayer) in the treatment of patients with deep vein thrombosis (DVT) have been ...

The NDA submission is supported by data from the phase 3 EINSTEIN-Jr and UNIVERSE trials in pediatric patients, along with adequate and well-controlled studies in adults. A New Drug Application (NDA) ...

Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used ...

Apixaban shows significantly lower bleeding risk than rivaroxaban in acute venous thromboembolism over 3 months in a ...

In this post, I will review these concerns and make the case that's it's too early to abandon rivaroxaban for stroke prevention in patients with AF. The new concern with ROCKET AF is an extension of ...

Please provide your email address to receive an email when new articles are posted on . “The mortality benefit demonstrated in the COMPASS trial ... is externally consistent with prior evidence of a ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The manufacturer's submission compared ...

The oral anticoagulant rivaroxaban is a safe and effective alternative to vitamin K antagonists for patients with atrial fibrillation (AF) undergoing cardioversion. This finding from the X-VeRT trial ...